Aseptic dry-powder filling of aztreonam for reconstitution into single-dose vials is validated around the arginine-buffered formulation rather than the unformulated API alone. The drug product composition uses an aztreonam-to-arginine mass ratio of 1:0.78 w/w, which buffers the reconstituted solution to a pH range of 4.5 to 7.5 and prevents solubility collapse during injection preparation. The sterile crystalline API is received with a residual moisture specification not exceeding 1.0% w/w and a bacterial endotoxin limit of 0.20 EU/mg when tested according to USP <85>. In filling, the powder is held in a dry room at relative humidity 15%–25% and temperature 20°C–25°C to limit β-lactam hydrolysis; this is the first critical control point because the API is not steam-sterilized and the final vial cannot be terminally heat-sterilized. The powder is dosed into depyrogenated Type I glass vials with an auger-driven or vacuum-assisted filler located in an ISO 5 unidirectional airflow isolator; fill weight is checked in-line with a reject limit of ± 2.0% of target. After filling, vials are nitrogen-flushed to achieve residual oxygen below 1.0% in the headspace, stoppered under partial vacuum, and sealed with aluminum flip-off caps. The final drug product must conform to USP <1>, USP <71>, USP <788>, USP <790>, USP <921>, USP <905>, 21 CFR 210/211, and EU GMP Annex 1. The terminal dosage type is a sterile powder for injection supplied as 1 g or 2 g aztreonam per vial; the powder is reconstituted with Sterile Water for Injection for intramuscular or intravenous administration, with intravenous infusion admixture concentration not exceeding 20 mg/mL to avoid precipitation during pH shift. Documented incompatibilities require separation from metronidazole and nafcillin in the same intravenous container or line.

Moisture control is the main process conflict in dry powder filling because aztreonam degrades by β-lactam hydrolysis when relative humidity exceeds 40%. The filling suite is therefore maintained at 15%–25% RH and 20°C–25°C; operators use isolated glove ports instead of open handling. Equipment qualification includes media fills under worst-case line speed and fill duration, with acceptance criteria of zero contaminated vials per 3000 filled vials per EU GMP Annex 1. The powder must be transferred from the API container to the filler hopper using split butterfly valves or equivalent containment to preserve sterility and reduce dust explosion risk. In-process bulk density and particle size are monitored because variation in powder flow can shift fill weight outside the ± 2.0% limit and alter reconstitution time. Reconstitution time in Sterile Water for Injection is controlled to not exceed 2 min with gentle agitation; prolonged shaking introduces foam that complicates dose withdrawal.

What Controls Blend Uniformity in Aztreonam-Avibactam Combination Vials?

Co-formulation of aztreonam with avibactam sodium produces a fixed-dose powder for concentrate for solution for infusion in a 3:1 mass ratio, as used in the 1.5 g/0.5 g presentation. The dominant formulation constraint is not potency loss during filling but segregation risk in the low-dose component. Avibactam sodium is present at only 25% of total mass and differs from aztreonam in bulk density, crystal habit, and electrostatic charge; this makes single-stage blending insufficient under USP <905> uniformity criteria. A two-stage blending process is conducted in a low-shear tumble blender at 60% vessel fill volume: avibactam sodium is first deagglomerated through a 500 µm cone mill and pre-blended with an equal mass of aztreonam for 15 min, then the pre-blend is added to the remaining aztreonam and blended for an additional 20 min. In-process blend uniformity is assayed with high-performance liquid chromatography; acceptance requires relative standard deviation not more than 5.0% for both aztreonam and avibactam. The blend is aseptically filled under EU GMP Annex 1 isolator conditions with residual moisture below 1.5% w/w and endotoxin below 0.20 EU/mg. Release testing follows USP <71>, USP <788>, USP <921>, and ICH Q3B. The terminal product is a sterile powder for reconstitution and further dilution for intravenous infusion; it is directed at complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired pneumonia, ventilator-associated pneumonia, and infections caused by carbapenem-resistant Gram-negative organisms producing metallo-β-lactamases. Renal dose adjustment is mandatory because both aztreonam and avibactam are renally cleared; the 1.5 g/0.5 g dose interval is extended in patients with reduced creatinine clearance to avoid accumulation.

Critical process parameters for the combination powder include blend fill depth, blender speed, and storage of the pre-blend under low-humidity conditions before filling. The pre-blend is stored in a nitrogen-purged stainless steel container at 20°C–25°C and 15%–25% RH for not more than 24 h before final filling to prevent moisture uptake. The filling line uses in-line checkweighing and rejects any vial outside ± 2.0% of target fill weight; fill weight variation for the low-dose avibactam component is indirectly controlled through blend uniformity because the two actives are not separated after blending. Terminal sterility is achieved by aseptic processing rather than moist heat, because both monobactam and avibactam sodium β-lactam rings degrade at steam sterilization temperatures. Release of the combination vial requires assay of both aztreonam and avibactam with limits of 95.0%–105.0% of label claim, and individual impurity limits per ICH Q3B. The powder for concentrate is reconstituted and further diluted before intravenous infusion; final admixture should be visually inspected and used within validated in-use stability periods to avoid precipitation in infusion lines.

Lysine Salt Conversion and Inhaled Solution Filling for Cystic Fibrosis

For inhalation delivery, aztreonam must be converted to aztreonam lysine to reach the solubility required for a 75 mg aztreonam equivalent per single-use ampoule after reconstitution with 1.0 mL of 0.17% sodium chloride diluent. The conversion process adds L-lysine to aztreonam in aqueous media under controlled pH; the reaction endpoint is judged by complete dissolution and a final solution pH between 4.2 and 5.8, below which free acid can precipitate and above which lysine crystallization can occur. The lysine salt solution or lyophilized powder is filled aseptically into low-density polyethylene ampoules under ISO 5 Grade A unidirectional airflow; terminal steam sterilization is not used because the β-lactam ring degrades rapidly at high temperature, and sterility is achieved by 0.22 µm filtration followed by aseptic fill. If the product is lyophilized, the cycle is designed to produce a fast-dissolving cake with residual moisture below 1.0% w/w and a sterility assurance level of 10⁻⁶ per USP <71>. Aerosol qualification is conducted with a vibrating mesh nebulizer; aerodynamic particle size distribution is measured by cascade impaction using USP <601> or Ph. Eur. 2.9.18, with mass median aerodynamic diameter controlled in the 2–5 µm range to balance central and peripheral pulmonary deposition. Delivered dose uniformity and fine particle fraction are tested to ensure lot-to-lot consistency through the specific nebulizer handset. The terminal product type is a sterile inhalation solution for cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infection; the product should be used only with the designated nebulizer system, as dose output varies with other devices. In-use stability limits require immediate nebulization after reconstitution and avoidance of exposure to heat above 25°C and prolonged light.

The process conflict in inhaled aztreonam is aerosol droplet coalescence and high-dose output variability through the vibrating mesh nebulizer. Filling volume precision is maintained at 1.0 mL ± 0.05 mL because the final dose is directly linked to fill volume and residual volume in the ampoule. The container-closure system is selected to minimize leachables and to resist breakage during transport of single-use ampoules; leachables testing is performed under USP <661> and pharmacopoeial elastomeric closure guidelines. Stability of the reconstituted solution is limited; therefore the product is packaged as a lyophilized powder plus separate sterile diluent to avoid aqueous hydrolysis of the β-lactam ring during storage. In-process controls include pH, osmolality, subvisible particulate matter per USP <788>, and delivered dose uniformity per USP <601>. The terminal product is not interchangeable with injectable aztreonam; the lysine salt and the inhalation-specific formulation differ in tonicity and aerosol performance, and substitution can cause airway irritation or subtherapeutic lung deposition.

Lyophilized aztreonam for injection uses a freeze-drying cycle designed around the amorphous collapse temperature of the frozen plug rather than the melting point of the API. The formulation is prepared by dissolving aztreonam with arginine or another buffer system at an API-to-bulking agent ratio between 1:0.5 and 1:1.5 w/w; mannitol is selected when a crystalline cake is required, while glycine is used when a low-reconstitution-time fragile cake is acceptable. The solution is filtered through a 0.22 µm sterilizing-grade membrane and filled at 1 g or 2 g aztreonam per vial. Freeze-drying proceeds with a primary drying shelf temperature of -30°C to -20°C and chamber pressure of 50–150 µbar, followed by secondary drying at 25°C to a final moisture endpoint below 1.0% w/w; product temperature must remain below collapse temperature throughout sublimation. The critical process failure is microcollapse, which produces high residual moisture and poor rehydration; therefore, process analytical technology using comparative pressure measurement or mass spectrometry is used to detect the end of primary drying. The finished dosage form is a sterile lyophilized powder or cake for reconstitution, with an endotoxin limit of 0.20 EU/mg and particulate matter limits per USP <788>. Compliance is maintained under USP <1>, USP <71>, USP <921>, ICH Q8, and EU GMP Annex 1. The terminal product type is a lyophilized vial for intravenous or intramuscular use after reconstitution; the lyophilized format is preferred when supply chain or hospital storage conditions involve high humidity, provided the cake is properly sealed with a moisture-protective closure.

Published data for this specific lyophilized configuration is limited; cycle parameters are established through freeze-drying microscopy and heat transfer characterization rather than by direct transfer from other β-lactams. The collapse temperature of the frozen plug is measured by differential scanning calorimetry and freeze-drying microscopy; the primary drying shelf temperature is set 1°C–3°C below the measured collapse temperature to avoid microcollapse. Heat transfer varies with vial size and shelf position; a loaded vessel must be mapped with thermocouples in edge and center positions before process validation. The vial stoppers are moisture-impermeable and are fully seated under vacuum to protect the cake from humidity during storage; storage temperature is controlled at 20°C–25°C and excursions above 25°C are limited to short periods.

Where Centralized Pharmacy Compounding Overlaps with Sterile API Handling

In hospital pharmacy cleanrooms, aztreonam sterile powder is reconstituted and diluted for patient-specific intravenous admixtures under USP <797> and USP <800>. The arginine-buffered powder yields a reconstituted concentration of 100 mg/mL when 1 g is diluted with 10 mL of Sterile Water for Injection; further dilution for infusion uses 0.9% sodium chloride injection or 5% dextrose injection, with final concentration not exceeding 20 mg/mL. The production process involves aseptic manipulation inside an ISO 5 primary engineering control; closed-system transfer devices are used when hazardous drug handling or multiple-dose batch preparation is required. The final admixture is inspected for visible particles and labeled with a beyond-use date assigned according to USP <797> category and local sterility data; low-risk compounded sterile products prepared in this environment are typically limited to 12 h or less at controlled room temperature. Terminal product types include single-patient intravenous infusion bags, elastomeric pumps for outpatient parenteral antimicrobial therapy, and syringe pumps for precisely adjusted doses in renal impairment. The main operational boundary is admixture compatibility: aztreonam should not be co-infused with other medications through the same intravenous line without validated compatibility data; documented incompatibilities require separation from metronidazole and nafcillin. Because published admixture stability data for this specific configuration is limited, line separation or dedicated infusion intervals are required in the absence of in-house testing.

Closed-system transfer devices and elastomeric pump filling introduce a second process boundary: adsorption or degradation of aztreonam during extended ambient exposure in ambulatory pumps. The admixture should be protected from light and maintained at controlled room temperature; when continuous infusion over 24 h is prescribed, the infusion bag must be kept below 25°C and the bag material must be compatible with β-lactam antibiotics. In-use stability is evaluated for the specific container closure system, because published data for aztreonam in elastomeric pump reservoirs is limited. The final product is patient-specific, not distributed as a licensed medicine; therefore each batch is prepared under pharmacy compounding regulations, and any deviation from the standard operating procedure triggers a quality event review.

Oral Granule and Tablet Formats Are Constrained by a Sub-1% Bioavailability Threshold

Oral solid dosage development for aztreonam is limited by gut-lumen hydrolysis and efflux transport; the drug has less than 1% absolute oral bioavailability, which excludes systemic tablet or capsule use unless the indication is strictly non-systemic gastrointestinal infection. No approved oral tablet or capsule is listed in the current FDA Orange Book; consequently, formulation addition ratios are not fixed by a reference product. Early granulation work for intestinal-targeted delivery typically starts with an API load of 20–40% w/w in a pH-sensitive enteric coating system, but published data for this specific configuration is limited, and a validated addition ratio must be generated through dissolution testing per USP <711>. The downstream production process for such a format would use high-shear granulation in a 25 L granulator, followed by extrusion-spheronization to produce granules with a target size of 0.8–1.2 mm, then enteric coating in a fluid bed processor to prevent gastric release. The terminal product type under investigation is a non-systemic oral granule for reconstitution or a delayed-release capsule for Gram-negative gut decolonization, but no compendial monograph or ICH harmonized specification currently exists; therefore each batch requires in-house dissolution, assay, and stability protocols aligned with ICH Q2(R1) and USP <711>. The primary incompatibility is with gastric acid: unprotected aztreonam undergoes pH-dependent degradation below pH 4.0, so the enteric coating must be intact after compression or encapsulation to prevent premature release.

The central incompatibility of unprotected aztreonam with gastric acid drives the need for an enteric coating with a dissolution threshold at pH 5.5 or higher. Granule core formulation must include a binder and disintegrant that do not raise the microclimate pH during storage because alkaline conditions accelerate aztreonam degradation. Bulk powder exposure to moisture above 30% RH during granulation or coating can initiate hydrolysis before the drug reaches the patient; therefore, the granulation and coating suite must be maintained under controlled humidity. Terminal product types under investigation include a delayed-release capsule and a sachet for oral suspension, but neither has a compendial monograph; characterization requires in-house dissolution, assay, and stability protocols aligned with ICH Q2(R1) and USP <711>.